Novo started the year on an impressive note, with growth again driven by the ever-growing GLP-1 diabetes franchise, and strong uptake for Wegovy. Moreover, sound progress on the pipeline front was encouraging. Having said that, Novo’s leadership in the obesity market is likely to be challenged by Eli Lilly’s upcoming drug Tirzepatide, which has shown much better results than Wegovy in clinical trials. The group’s enduringly-expensive valuation is an added impediment to our turning positive on th ....
29 Apr 2022
Strong start to the year; but watch-out for brewing competition in obesity
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong start to the year; but watch-out for brewing competition in obesity
- Published:
29 Apr 2022 -
Author:
Amandeep Goyal -
Pages:
5
Novo started the year on an impressive note, with growth again driven by the ever-growing GLP-1 diabetes franchise, and strong uptake for Wegovy. Moreover, sound progress on the pipeline front was encouraging. Having said that, Novo’s leadership in the obesity market is likely to be challenged by Eli Lilly’s upcoming drug Tirzepatide, which has shown much better results than Wegovy in clinical trials. The group’s enduringly-expensive valuation is an added impediment to our turning positive on th ....